Tag: M.W:200-300

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.89891-65-6,7-Bromo-2-chloroquinoxaline,as a common compound, the synthetic route is as follows.

[0305] To a solution of 7-bromo-2-chloroquinoxaline (10 g, 41 mmol, 1 eq.) in CH3OH ( 200 mL) was added K2C03 ( 12.4 g, 91 mmol, 2 eq). The resulting mixture was stirred under reflux for 2h, then cooled to rt and concentrated. The resulting residue was dissolved in THF and filtered. The filtrate was concentrated to afford 7-bromo-2-methoxyquinoxaline as a white solid (9.88 g, 100%).

89891-65-6, 89891-65-6 7-Bromo-2-chloroquinoxaline 4913253, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; NEUPHARMA, INC.; QIAN, Xiangping; ZHU, Yong-liang; WO2013/40515; (2013); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

108229-82-9, 6-Bromo-2,3-dichloroquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of compound 1 (2.78 g, 0.01 mol)and arylthiosemicarbazone (0.01 mol) in absolute ethanol (50 mL) was refluxed for 4-5 h. After completion of the reaction, the reaction mixture was cooled and the precipitate that formed was filtered, dried and crystallized from benzene to produce the corresponding compounds.

108229-82-9, The synthetic route of 108229-82-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Abbas, Hebat-Allah S.; Al-Marhabi, Aisha R. M.; Ammar, Yousry A.; Acta poloniae pharmaceutica; vol. 74; 2; (2017); p. 445 – 458;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2958-87-4,2,3,6-Trichloroquinoxaline,as a common compound, the synthetic route is as follows.

EXAMPLE 2 9-Chloro-1,2,3,4,4a,5-hexahydropyrido[1′,2′:4,5][1,4]oxazino[2,3-b]quinoxaline and 10-chloro-1,2,3,4,4a,5-hexahydropyrido[1′,2′:4,5][1,4]oxazino[2,3-b]quinoxaline A mixture of 23.3 g. of 2,3,6-trichloroquinoxaline, 11.5 g. of 2-piperidinomethanol, 40 ml. of triethylamine and 400 ml. of dimethylformamide is stirred at room temperature for 4 hours and then heated on a steam bath for 48 hours. A 500 ml. portion of water is added dropwise. The solid is recovered by filtration, washed with water and air dried. This solid is dissolved in dichloromethane, passed through Magnesol and recrystallized from ethyl acetate. Recrystallization from ethanol or ethyl acetate gives pale yellow crystals of 10-chloro-1,2,3,4,4a,5-hexahydropyrido[1′,2′:4,5][1,4]oxazino[2,3-b]quinoxaline, m.p. 147-149 C. Fractional crystallization from the mother liquor gives a second yield of the above 10-chloro derivative plus 9-chloro-1,2,3,4,4a,5-hexahydropyrido[1′,2′:4,5][1,4]oxazino[2,3-b]quinoxaline, m.p. 107-109 C. The monohydrochloride salts of both compounds may be prepared as described in Example 1 and decompose above 300 C., 2958-87-4

2958-87-4 2,3,6-Trichloroquinoxaline 18070, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; American Cyanamid Company; US4200748; (1980); A;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.36856-91-4,2-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

A 25-mL round bottom flask equipped with a magnetic stirrer,a condenser and a nitrogen in/outlet adapter was charged with2-bromoquinoxaline (13 mg, 0.063 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-carbomethoxy-4?-(t-butyl)phenyl-[1,1?]biphenyl (25 mg, 0.063mmol), water/dioxane (1.0 mL/4.0 ml), K2CO3 (17 mg, 0.126mmol). The resulting solution wasdegassed for 15 min, then Pd(PPh3)4 (5 mg) wasadded. The reaction mixture was warmedto 100oC and stirred for 1 h.After cooled to room temperature, the reaction mixture was diluted withEtOAc and washed with saturated NaHCO3, brine, dried over Na2SO4.The organic layer was concentrated in rotavapor and purified on silicagel. Elution with 10 % EtOAc/hexanessolvent system afforded the desired compound (15 mg, 60 % yield) . 1HNMR (300 MHz, CDCl3) delta 9.46 (s, 1H), 8.83 (s, 1H), 8.69 (m, 1H),8.46 (s, 1H), 8.21 (m, 2H), 7.86 (m, 2H), 7.72 (d, J =12.0 Hz, 2H), 7.58 (d, J= 12.0 Hz, 2H), 4.05 (s, 3H), 1.42 (s, 9H).

36856-91-4, The synthetic route of 36856-91-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Parhi, Ajit K.; Zhang, Yongzheng; Saionz, Kurt W.; Pradhan, Padmanava; Kaul, Malvika; Trivedi, Kalkal; Pilch, Daniel S.; Lavoie, Edmond J.; Bioorganic and Medicinal Chemistry Letters; vol. 23; 17; (2013); p. 4968 – 4974;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

36856-91-4, 2-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

2-Bromoquinoxaline 50 (350 mg, 1.67 mmol, 1 eq) was dissolved in EtOAc (16 ml). Octanal (1.05 ml,6.715 mmol, 4 eq) and TMSN3 (0.44 ml, 6.698 mmol, 2 eq) were added. Phi(OCOCF3)2 (1.44 g, 6.698mmol, 2 eq) was added portionwise over 10 min and the mixture turned orange in colour. The mixturewas stirred at room temperature for 2 h. Further TMSN3 (0.44 ml, 6.698 mmol, 2 eq) and Phi(OCOCF3)220 (1.44 g, 6.698 mmol, 2 eq) were added and reaction was stirred for 18 h. Triethylamine (2 ml) was addeddropwise and the mixture was stirred for 15 min. The reaction mixture was concentrated and the crudemixture was purified by silica gel column chromatography (50:1 pentane: EtOAc) to afford product 51 as ayellow solid (259 mg, 61%). Rt = 0.38 (10:1 cyclohexane: EtOAc); m.p. = 43-48 oc; 1H NMR (400 MHz,CDCI3) o 8.16-8.04 (m, 2H), 7.90-7.81 (m, 2H), 3.18 (t, J = 7.5 Hz, 2H), 1.83-1.75 (m, 2H), 1.44-25 1.28 (m, 8H), 0.89 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz, CDCI3) o 201.5, 149.8, 143.3, 139.6, 134.8,132.6, 131.2, 129.8, 128.61, 40.7, 31.8, 29.3, 29.2, 23.7, 22.8, 14.2; IR (CHCI3) (vmax, cm-1) 3429, 1708,1560; HRMS (ESI) [M + Hf calc 335.0759 for C16H20N20 79Br, found 335.0759., 36856-91-4

The synthetic route of 36856-91-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; UNIVERSITY COLLEGE DUBLIN; GUIRY, Patrick; GODSON, Catherine; (148 pag.)WO2018/33642; (2018); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

98416-72-9, 6-Bromo-2-chloro-3-methylquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,98416-72-9

4.14 4-(-6-Bromo-3-methylquinoxalin-2-yloxy)benzaldehyde (14) p-Hydroxybenzaldehyde (0.01 mol) was dissolved in a mixture of acetonitrile (50 mL) and DMF (5 mL) containing anhydrous potassium carbonate (2.0 g). The mixture was refluxed for 1 h, then compound (5, 0.01 mol) was added and the mixture was further refluxed for 19 h (monitored by TLC). After completion of the reaction, the mixture was filtered and the excess of acetonitrile was evaporated under reduced pressure, dried and crystallized from mixture of benzene and petroleum ether to yield the crude product. Yield: 76%; (orange-brown powder): mp 101-103 C; IR (KBr) numax in cm-1: 2921 (aliphatic C-H), 2837, 2720 (CH-aldehyde), 1697 (C=O), 1597 (C=N); 1H NMR (DMSO-d6, 500 MHz): delta 2.74 (s, 3H, CH3), 7.58-8.04 (m, 7H, Ar-H), 10.04 (s, 1H, CHO); 13C NMR (DMSO-d6, 125 MHz): delta 20.49 (CH3), 122.47-133.54 (12Ar-C), 148.90, 149.52 (2C=N), 190.87 (CHO); MS (m/z), 342 (M+; 100%), 343 (M++1; 27%), 344 (M++2; 96%). Anal. Calcd for C16H11BrN2O2 (343.17): C, 56.00; H, 3.23; N, 8.16. Found: C, 56.19; H, 3.45; N.

98416-72-9 6-Bromo-2-chloro-3-methylquinoxaline 13487186, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Article; Abbas, Hebat-Allah S.; Al-Marhabi, Aisha R.; Eissa, Sally I.; Ammar, Yousry A.; Bioorganic and Medicinal Chemistry; vol. 23; 20; (2015); p. 6560 – 6572;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

53967-21-8, 6-(Bromomethyl)quinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

53967-21-8, Example 25 6-({4-[2-(4-tert-butylphenyl)-1,3-benzoxazol-7-yl]piperazin-1-yl}methyl)quinoxaline: To a suspension of 2-(4-tert-butylphenyl)-7-piperazin-1-yl-1,3-benzooxazole 23.5 mg, 0.070 mmol) and 6-bromomethylquinoxaline (17.2 mg, 0.077 mmol) in CH3CN (anh., 10 mL) was added ethyldiisopropylamine (0.015 mL, 0.084 mmol). The mixture was heated in a 95 C. bath overnight. The reaction was cooled to room temperature and concentrated in vacuo. The residue was adsorbed onto silica gel. Silica gel chromatography using a gradient of 25% EtOAc/hexane to 50% EtOAc/hexane then 100% EtOAc afforded the title compound (23.2 mg) as an ivory powder. MS (ESI) m/z 478 [M+H]+; HPLC Method C, r.t.=10.9 min (98.9% a210-370 nm; 97.4% a 236 nm).

As the paragraph descriping shows that 53967-21-8 is playing an increasingly important role.

Reference£º
Patent; Wyeth; US2006/264631; (2006); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

50998-17-9, 6-Bromo quinoxaline (2.0 g, 9.5 mmol) in toluene (20 ml.) was degassed for 30 min. To this solution, 1-ethoxy vinyl tributyltin (3.8 g, 10.5 mmol) and bis(triphenylphosphine)palladium dichloride (0.67 g, 0.95 mmol) were added at rt and stirred for 16 hours at 90 C. The reaction mixture was cooled to rt and filtered through celite. After evaporation of the solvent, 6 N HCl solution in water (20 ml.) was added and the mixture was stirred for 1 hour at rt. It was concentrated and neutralized with sat. NaHCO3. The desired product was extracted with DCM (100 mL,), dried over Na2SO4 and concentrated. The crude product was purified by flash column chromatography to afford the title compound (brown solid). 1H NMR (400 MHz, DMSO-d6): delta 9.06-9.04 (m, 2H), 8.70 (d, J=2.4 Hz, 1H), 8.28 (t, J = 2.8 Hz, 1H), 8.16 (d, J = 11.6 Hz, 1H), 2.97 (s, 3H). LCMS: (Method A) 173 (M+H), Rt. 2.25 min, 99.06% (Max).

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; ASCENEURON SA; QUATTROPANI, Anna; KULKARNI, Santosh S.; GIRI, Awadut Gajendra; (243 pag.)WO2016/30443; (2016); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

A degassed mixture of the crude 3-(3-pyrrolidin-1-yl-prop-1-ynyl)-2-trimethylstannanyl-imidazo[1,2-a]pyridine-6-carboxylic acid bis-(3-methyl-butyl)amide (ca. 262 mg) and 6-bromoquinoxaline (96 mg) in DMF (3 ml) was treated with Pd(PPh3)4 (48 mg). The reaction mixture was transferred to a pre-heated oil bath (110C) and stirred in a sealed tube at this temperature for 18 h. The mixture was diluted with diethyl ether (25 ml) and washed with water (1 x 20 ml). The aqueous layer was extracted with diethyl ether (2 x 15 ml). The combined organic extracts were washed with brine (30 ml), dried over sodium sulfate, filtered, and evaporated. The crude product was isolated by column chromatography and re-purified by preparative HPLC-MS., 50998-17-9

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; Santhera Pharmaceuticals (Schweiz) AG; EP2168965; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1210048-05-7,7-Bromo-5-fluoroquinoxaline,as a common compound, the synthetic route is as follows.

Under an argon atmosphere, 750 mg (0.819 mmol) of tris-(dibenzylidene-acetone)-dipalladium(0) and 551 mg (1.966 mmol) of tricyclohexylphosphine were dissolved in 80 ml dioxane. |814 mg – -(15.019 mmol) of 4,4,414’5,5,5’5′-octamethyl-2,2t-bi-l,3,2-dioxaborolan, 3100 mg (13.654 mmol) of the compound from example 9OA and 2010 mg (20.4813 mmol) potassium acetate were added and the mixture was stirred overnight at 800C. After cooling, dioxane was added to the reaction mixture and it was filtered on Celite. The filtrate was concentrated in a rotary evaporator at reduced pressure and dried under high vacuum. We obtained 7.08 g of the raw product (purity 69% according to GC-MS), which was reacted further without further purification.GC-MS (method 6): R, = 6.78 min; MS (EIpos): m/z = 274 [M]+., 1210048-05-7

1210048-05-7 7-Bromo-5-fluoroquinoxaline 59286334, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT; BAeRFACKER, Lars; KAST, Raimund; GRIEBENOW, Nils; MEIER, Heinrich; KOLKHOF, Peter; ALBRECHT-KUePPER, Barbara; NITSCHE, Adam; STASCH, Johannes-Peter; SCHNEIDER, Dirk; TEUSCH, Nicole; RUDOLPH, Joachim; WHELAN, James; BULLOCK, William; PLEASIC-WILLIAMS, Susan; WO2010/20363; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider